Torch Ginger for Digestive Complaints and Gastric Protection

Torch ginger's parent page mentions the flower bud only in passing as "a digestive and appetite-stimulating vegetable." Two more specific traditional claims exist in the pharmacological literature and are not currently named on that page at all: the rhizome's folk reputation for easing stomach discomfort, and a documented traditional use as an antidiabetic spice in Aceh Province, Sumatra. Neither is a culinary use of the part actually eaten, and neither is proof of anything. What follows is the real trail: where those two claims come from, and what a genuine, fast-moving 2020–2026 research cluster has and has not shown about torch ginger and the gut.

Table of Contents

  1. Two Traditional Claims Missing From the Parent Page
  2. The Mechanism Being Tested: NF-κB, iNOS, and Ulceration
  3. Flower Extract Against Gastric Ulcers (2020)
  4. Inflorescence Extract Against Ethanol-Induced Ulcers (2025)
  5. A Direct Enzyme Test: Cyclooxygenase Inhibition (2026)
  6. The Alpha-Glucosidase Finding, and Which Part Actually Wins
  7. Diabetes as an Inflammatory Complication: Kidney and Gum Models
  8. What a Real Trial Would Need to Show
  9. Cautions
  10. Key Research Papers
  11. Connections

Two Traditional Claims Missing From the Parent Page

Juwita and colleagues, introducing their 2020 gastric-ulceration study, state plainly that the Etlingera elatior rhizome "has been traditionally used to reduce stomach discomfort" and that prior work had already reported anti-inflammatory activity for the rhizome — their own contribution was testing whether the flower, the part people actually eat, shares that property, since at the time it had never been tested. That is a specific, named, citable traditional use of a non-culinary part of this plant, and it does not appear anywhere on the parent page's traditional-use section.

Separately, Zumaidar and colleagues (2024) open their alpha-glucosidase study by stating that "Etlingera elatior has been widely used as spice and traditional medicine to treat diabetes in Aceh Province, Indonesia." This is also absent from the parent page, which lists wound care, earache, cough, breath and body odor, and appetite stimulation as the plant's folk uses, but not diabetes. Both omissions point the same direction: the parent page's traditional-use section, accurate as far as it goes, is not complete, and the gap happens to line up exactly with where the modern pharmacology literature has concentrated its attention.

As always, a traditional claim is history, not proof. What makes this pair of claims unusually interesting is that both now have real, recent laboratory work pointed directly at them — not retrofitted after the fact, but in two cases (Juwita, Zumaidar) named as the explicit motivation for the study.

Back to Table of Contents

The Mechanism Being Tested: NF-κB, iNOS, and Ulceration

Every study in this section tests some part of the same inflammatory cascade. Gastric mucosal damage — from alcohol, from excess stomach acid, from a bacterial trigger like H. pylori — generates reactive oxygen species that activate the transcription factor NF-κB. Active NF-κB drives expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), both of which amplify local inflammation and, at excess levels, actively worsen mucosal injury rather than protect it. This is the same pathway targeted by several classes of prescription anti-inflammatory drugs, and it is the pathway every torch ginger gastric study below actually measures — not "does the stomach feel better," which nobody has asked a person, but "does NF-κB/iNOS/COX-2 activity go down in a rat's stomach tissue after this extract."

Back to Table of Contents

Flower Extract Against Gastric Ulcers (2020)

Juwita and colleagues induced gastric ulceration in Wistar rats and treated groups with flower extract at 500, 1,000 and 2,000 mg/kg body weight, against a normal control, a negative control, and a positive control (quercetin, itself a flavonoid with known anti-inflammatory activity). The 1,000 mg/kg dose reduced both the ulceration index and inflammatory-cell infiltration, and Western blot confirmed reduced NF-κB-p65 expression in the stomach fundus at that dose. Notably, the effect was dose-non-linear in the reporting — 1,000 mg/kg is highlighted as effective, not the highest 2,000 mg/kg dose, which is worth flagging rather than assuming "more is better" the way marketing copy tends to.

Back to Table of Contents

Inflorescence Extract Against Ethanol-Induced Ulcers (2025)

Two companion papers from an Indonesian-Thai collaboration (Prayoga and colleagues) extended this work five years later, using fresh inflorescence petals collected in West Java and an ethanol-induced ulcer model — a standard, well-validated way to chemically injure the gastric mucosa in rats. At 625 mg/kg over five days of oral dosing, the extract reduced the ulcer index and, in the authors' words, provided "100% protection" at that specific dose, while suppressing iNOS expression in both its cleaved and full-length forms. A striking single-study number like that is worth flagging for what it is: one dose, one model, one paper, not yet independently repeated, and the authors themselves close by calling for further work in chronic ulcer models rather than claiming the question is settled.

The companion paper profiled the same inflorescence extract's chemistry — anthocyanins (47.5 mg/100 g), vitamin C (985 mg/100 g of the extract, not the fresh flower as eaten), cyanidin-3-glucoside and quercetin — and used molecular docking to predict which of these compounds bind the iNOS catalytic site, before confirming with a real in vitro enzyme assay that the whole extract inhibits human iNOS with an IC50 of 24.7 µg/mL. The docking component is the weakest part of this evidence: it predicts binding on a computer, it does not confirm a physiological effect. The in vitro enzyme-inhibition result is the real finding; the docking is context for which compounds are the likely drivers.

Back to Table of Contents

A Direct Enzyme Test: Cyclooxygenase Inhibition (2026)

A 2026 paper (Alcano and colleagues) took a different, complementary approach: comparing inflorescence extracts of torch ginger against Hornstedtia conoidea, a Philippine-endemic relative, for direct COX-1 and COX-2 inhibition in vitro. Torch ginger's crude extract showed stronger COX inhibition than its comparator, with molecular dynamics simulations suggesting oligomeric procyanidins favor COX-1 while flavonoid glycosides favor COX-2. This is a real in vitro enzyme-inhibition result, independent of the iNOS work above, converging on the same general conclusion: whatever is in the flower/inflorescence fraction of this plant does, reproducibly, blunt inflammatory-enzyme activity in a dish. NSAIDs work through this exact enzyme family, which is precisely why the authors frame this as a search for "natural alternatives" with potentially better isoform selectivity — a real pharmacological hypothesis, not yet tested in any animal or person.

Back to Table of Contents

The Alpha-Glucosidase Finding, and Which Part Actually Wins

Zumaidar and colleagues (2024), motivated by the Aceh traditional antidiabetic use above, compared stem, rhizome, leaf and fruit extracts from the same plants side by side. The results resist a simple "torch ginger is antidiabetic" headline, because the four parts did not agree with each other:

Alpha-glucosidase is the intestinal enzyme that breaks starch fragments into absorbable glucose; blocking it is the mechanism of the prescription diabetes drug acarbose, a licensed drug class with a known, modest effect on HbA1c (typically a 0.5–0.8 percentage point reduction in trials). That is a useful ceiling to keep in mind: even a perfect natural analog of acarbose's mechanism would be expected to produce a modest effect, not a dramatic one — and what exists here is a single in vitro enzyme assay on an extract of the stem, a part with no culinary tradition at all, not a clinical glucose-lowering trial of anything a person would actually eat.

Back to Table of Contents

Diabetes as an Inflammatory Complication: Kidney and Gum Models

Two further rat studies test torch ginger extract not against blood glucose directly, but against the downstream inflammatory complications of diabetes — a different, related question.

Chronic kidney disease (Widyarini and colleagues, 2022). Mice with streptozotocin-nicotinamide-induced diabetes, hypertension, and surgically induced kidney obstruction were treated with ethanol extract at 200–800 mg/kg. The higher doses (600–800 mg/kg) improved plasma glucose, blood pressure, creatinine, albuminuria, and the inflammatory marker hs-CRP, with corresponding improvement in kidney histology. The abstract's own wording briefly attributes part of the effect specifically to "vanillic acid," a compound within the extract, without full clarity in the available summary on how that attribution was isolated from the whole-extract data — worth naming honestly as an ambiguity in the published summary rather than either asserting or dismissing the compound-level claim.

Diabetic periodontitis (Syaify and colleagues, 2024). Rats with streptozotocin-induced diabetes and periodontitis received daily flower extract by intraperitoneal injection — not orally, a route substitution worth flagging explicitly, since an injected preparation says nothing about what eating the vegetable does. COX-2 expression in the gum tissue was measured across seven days and the result was genuinely biphasic: COX-2 was higher in the treated group on days 1 through 5, then significantly lower than the saline group by day 7. A simple "reduces inflammation" summary would misrepresent this result; the actual finding is a time-dependent modulation, higher before it is lower, and the authors frame the extract as a "host modulation therapy" component on that basis rather than a straightforward anti-inflammatory.

Back to Table of Contents

What a Real Trial Would Need to Show

None of the above is a test of the traditional claim in the form anyone would actually use it — a person eating the flower bud for stomach discomfort. A real test would need a validated dyspepsia symptom score or endoscopy-confirmed ulcer healing rate, a defined culinary or standardized-extract dose taken orally, a placebo or active comparator (quercetin already has a role as a positive control in the rat literature; a proton-pump inhibitor would be the realistic clinical comparator), and a large enough human sample to detect a clinically meaningful difference. Nothing resembling this exists for torch ginger, in any part, at any dose. What exists is a consistent, mechanistically coherent, entirely preclinical signal — three independent research groups, three different extraction approaches, one converging pathway — that has never been asked whether it holds up in a person.

Back to Table of Contents

Cautions

Back to Table of Contents

Key Research Papers

  1. Juwita T, H P Pakpahan W, M Puspitasari I, Mekar Saptarini N, Levita J. Anti-inflammatory activity of Etlingera elatior (Jack) R.M. Smith flower on gastric ulceration-induced Wistar rats. Pakistan Journal of Biological Sciences, 2020. — PubMed search
  2. Prayoga DK, Aulifa DL, Budiman A, Levita J, Jiranusornkul S. Etlingera elatior inflorescence extract mitigates acute gastric ulcers by suppressing the expression of inducible nitric oxide synthase in ethanol-induced Wistar rats. Journal of Experimental Pharmacology, 2025. — PubMed search
  3. Prayoga DK, Pitaloka DAE, Aulifa DL, Budiman A, Levita J, Jiranusornkul S, Nguyen BP. Phytochemical analysis, computational study, and in vitro assay of Etlingera elatior inflorescence extract towards inducible nitric oxide synthase. Journal of Experimental Pharmacology, 2025. — PubMed search
  4. Alcano JC, Laserna AKC, Quimque MTJ, Pelobello DHD, Camacho DH, Barbosa GB. LC-MS/MS metabolite profiling, molecular networking and cyclooxygenase inhibition activity of Hornstedtia conoidea and Etlingera elatior extracts. Journal of Pharmaceutical and Biomedical Analysis, 2026. — PubMed search
  5. Zumaidar Z, Asmilia N, Saudah S, Husnah M. In vitro alpha-glucosidase inhibitory effect of Etlingera elatior ethanol extract growing in Gayo Highland, Aceh Province, Indonesia. F1000Research, 2024. — PubMed search
  6. Widyarini T, Indarto D, Soetrisno S, Purwanto B. Modulation effects of Etlingera elatior ethanol extract as anti-inflammatory on chronic kidney disease in mice with hypertension and diabetes. Journal of Population Therapeutics and Clinical Pharmacology, 2022. — PubMed search
  7. Syaify A, Sari R, Alhasyimi AA. Effects of Etlingera elatior flower extract on cyclooxygenase-2 expression in the gingival epithelium in a diabetic periodontitis rat model. Journal of Taibah University Medical Sciences, 2024. — PubMed search
  8. Nurhayatun E, Purwanto B, Ulfia M. Effects of NADPH oxidase inhibitor of the Etlingera elatior fruit extracts in animal sepsis models. Tropical Biomedicine, 2024. — PubMed search
  9. Zendrato HM, Masruchin N. Trends and multidisciplinary research of torch ginger [Etlingera elatior (Jack) R.M.Sm.]: a systematic review. Journal of Ethnopharmacology, 2026. — PubMed search
  10. Juwita T, Puspitasari IM, Mustarichie R, Levita J. Torch ginger (Etlingera elatior): a review on its botanical aspects, phytoconstituents and pharmacological activities. Pakistan Journal of Biological Sciences, 2018. — PubMed search

Back to Table of Contents

Connections

Back to Table of Contents